

Product Data Sheet

Product Name: SPHINX
Cat. No.: GC65981

Chemical Properties

Cas. No. 848057-98-7


Formula $C_{17}H_{17}F_3N_2O_3$ M.Wt 354.32

Solubility DMSO : 50 mg/mL (141.12 mM; ultrasonic and warming and heat to 60°C) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

IC₅₀: 0.58 μ M (SRPK1)^[1]

SPHINX is a selective **SRPK1** inhibitor with an **IC₅₀** value of 0.58 μ M. SPHINX effectively reduces Choroidal Neovascularization (CNV) in vivo. SPHINX can be used for the research of (age-related macular degeneration) AMD^[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

SPHINX (10 μ M; 2 h) affects EGF-induced phosphorylation of SRSF1 and SRSF2 [1].

SPHINX (5 μ M; 24 h) reduces the expression of VEGF165 relative to GAPDH control either in primary RPE and ARPE-19 cell lines[1].

Western Blot Analysis[1]

Cell Line: ARPE-19 cell line

Concentration: 10 μ M

Incubation Time: 2 hours

Result: Blocked EGF-induced phosphorylation of SRSF1 and SRSF2.

SPHINX (10 ng; i.o. on laser photocoagulation day 0 and day 7) affects neovascular growth in vivo [1].

SPHINX (25 ng; i.o. on laser photocoagulation day 0 and day 7) affects the CNV area in CNV rats [1].

Animal Model: C57/B6 mice with laser-induced CNV[1]

Dosage: 10 ng

Administration: Intraocular injection; 10 ng on laser photocoagulation day 0 and day 7

Result: Significantly reduced neovascular growth compared with saline-injected controls.

Animal Model: Norway Brown rats with laser-induced choroidal neovascularization [1]

Dosage: 25 ng (10 ng/ μ L)

Administration: Intraocular injection; 25 ng (10 ng/ μ L) on laser photocoagulation day 0 and day 7

Result: Significantly reduced the CNV area compared with saline injected controls.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA